News / Africa

Starting AIDS Treatment Much Earlier May Mean Longer, Healthier life


Joe DeCapua

Over the years, there’s been debate over when to start HIV-positive patients on anti-retroviral drugs, or ARVs.  At first the standard practice was to wait until a person’s immune system had nearly collapsed.  But a growing body of research shows there may be many benefits to starting treatment much earlier.

Measuring the number of CD4 immune cells is a major determining factor on when to begin drug treatment.  It was the norm to give ARVs to people who either had full-blown AIDS or had CD4 counts below 200.

Now it’s generally accepted that anti-retrovirals should be given when the count drops below 350.  But there’s debate over whether to start treatment even earlier than that.

Dr. Roy Gulick, Weill-Cornell Medical Center
Dr. Roy Gulick, Weill-Cornell Medical Center

The subject was discussed at the recent OPMAN XVIII, the Optimal Management of HIV Disease Conference.  

Dr. Roy Gulick, professor of medicine at the Weill-Cornell Medical Center in New York City, says, “It’s ironic that 23 years now into anti-retroviral therapy we are still asking a very basic question.  And that is, when should we start?”

Pros and cons

Gulick outlines a few reasons for starting anti-retroviral treatment early.

“We know that our treatment decreases viral load levels and thus the emergence of (drug) resistance and also increases CD4 cell counts and general immune function.  We have published data to show that our best regimens can suppress viral load levels for up to seven years or longer,” he says

What’s more, he says, “Treatment likely reduces transmission in the community.  That is, treatment can be prevention.”

Starting earlier may also be more cost effective.

Some of the reasons for delaying treatment have included the inconvenience and toxicity of anti-retrovirals and their long-term side effects.  

“On balance, up until recently, we have elected to wait to start.  But there is a lot of data, newer data, to suggest that the balance of this question is likely shifting,” he says.

There had been general agreement that ARV treatment should be started for anyone with AIDS, symptomatic HIV disease or CD4 counts less than 200.

But there’s now agreement on a second group with a higher count.

“That is asymptomatic with CD4s between 200 and 350.  The developed country guidelines all changed to a firm yes in 2008.  And the newest guidelines to now suggest this are the WHO (World Health Organization) ’09 guidelines, which now say, yes, we should be treating anyone with HIV disease, regardless of symptoms, with a CD4 (count) less than 350,” he says.

A study in Haiti helped persuade the World Health Organization to recommend starting treatment earlier.  Fewer deaths and infections were found in those who received ARVs sooner.  Besides a drop in mortality, earlier treatment resulted in fewer tuberculosis cases among patients.

“This was the data that caught the eye of the WHO and really the world and said that we should be starting earlier throughout the world,” he says.

Gulick says the shift to earlier treatment is also due, in part, to “easier, less toxic and more potent therapy.”

He says, “So we go from handfuls of 20 plus pills taken three times daily to as few as one pill once a day.”

Starting AIDS Treatment Much Earlier May Mean Longer, Healthier life
Starting AIDS Treatment Much Earlier May Mean Longer, Healthier life

There are also the findings of many cohort studies to support earlier treatment. The findings are based on thousands of HIV patients, whose progress was followed in clinics.

In 2002, in one study, no difference was seen in those receiving treatment when their CD4 counts were between 200 and 350 and those who started treatment when their counts were over 350.  At least that was the case after comparing the two groups over a three-year period.

“Although there’s no difference at three years,” he says, “at five years, this now reaches statistical significance.  So, there was a benefit to starting earlier in this cohort study.  And it took over three years, more like five years, to convincingly show the clinical benefit here.”

Proof enough?

The professor of medicine asks if the results appear good for those receiving treatment at this stage, why not start even earlier? In other words, a CD4 count above 350.  Some cohort studies seem to support this, but Gulick says those studies are not always enough to go on.

“Well, what’s the problem with all the data I’ve shown you so far?  And that is it’s not randomized clinical trial data.  These are cohort patients.  That is, general patients followed in clinics,” he says.

And these patients may be different.

“It’s safe to say that patients who elect to start ART (anti-retroviral therapy) with high CD4s may not be the same as patients who defer ART with the same high CD4s,” he says.

Those who choose to start treatment sooner may have better health habits.  

“They may use seatbelts more.  They may exercise more.  There may be other confounding reasons why they have general better health than the group who elects to defer.  So we have to take all this cohort data somewhat with a grain of salt,” Gulick says.

And some cohort studies found starting treatment at a much higher 450 to 550 CD4 count showed no significant benefits.

To try to settle the issue, a formal clinical study – the Start study – is now underway.  It’s enrolled patients with CD4 counts higher than 500.  The study could finally determine whether it’s more beneficial to start treatment immediately or wait until CD4s drop below 350, the current standard.  However, the results may not be known for six years.  

Some say the there’s enough data from the cohort studies to not wait for the Start study results.  

You May Like

800-Pound Man Determined to Slim Down

Man says he was kicked out of hospital for ordering pizza; wants to be an actor More

Australia Prepares to Resettle 12,000 Syrian Refugees

Preference will be given to refugees from persecuted minorities, and the first group is expected to arrive before late December More

S. African Miners Seek Class Action Suit Against Gold Mines

The estimated 100,000 say say they contracted the lung diseases silicosis and tuberculosis in the mines More

This forum has been closed.
There are no comments in this forum. Be first and add one

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Amnesty Accuses Saudi Coalition of ‘War Crimes’ in Yemeni
Henry Ridgwell
October 12, 2015 4:03 PM
The human rights group Amnesty International has accused the Saudi-led coalition of war crimes in airstrikes against Houthi rebels in Yemen. Henry Ridgwell reports the group says hundreds of civilians have been killed in strikes on residential areas.

Video Amnesty Accuses Saudi Coalition of ‘War Crimes’ in Yemen

The human rights group Amnesty International has accused the Saudi-led coalition of war crimes in airstrikes against Houthi rebels in Yemen. Henry Ridgwell reports the group says hundreds of civilians have been killed in strikes on residential areas.

Video No Resolution in Sight to US House Speaker Drama

Uncertainty grips the U.S. Congress, where no consensus replacement has emerged to succeed Republican House Speaker John Boehner after his surprise resignation announcement. Half of Congress is effectively leaderless weeks before America risks defaulting on its national debt and enduring another partial government shutdown.

Video New Art Exhibit Focuses on Hope

Out of struggle and despair often comes hope. That idea is behind a new art exhibit at the American Visionary Art Museum in Baltimore, Maryland. "The Big Hope Show" features 25 artists, some of whom overcame trauma and loss. VOA’s Deborah Block reports.

Video Columbus Day Still Generates Controversy as US Holiday

The second Monday of October is Columbus Day in the United States, honoring explorer Christopher Columbus and his discovery of the Americas. The achievement is a source of pride for many, but for some the holiday is marked by controversy. Adrianna Zhang has more.

Video Anger Simmers as Turks Begin to Bury Blast Victims

The Turkish army carried out new air strikes on Kurdistan Workers Party (PKK) targets on Sunday, a day after the banned group announced a unilateral cease fire. The air raids apparently are in retaliation for the Saturday bombing in Turkey's capital Ankara that killed at least 95 people and wounded more than 200 others. But as Zlatica Hoke reports, there are suspicions that Islamic State is involved.

Video Bombings a Sign of Turkey’s Deep Troubles

Turkey has begun a three-day period of mourning following Saturday’s bomb attacks in the capital, Ankara, that killed nearly 100 people. With contentious parliamentary elections three weeks away, the attacks highlight the challenges Turkey is facing as it struggles with ethnic friction, an ongoing migrant crisis, and growing tensions with Russia. VOA Europe correspondent Luis Ramirez reports.

Video Afghanistan’s Progress Aided by US Academic Center

Recent combat in Afghanistan has shifted world attention back to the central Asian nation’s continuing civil war and economic challenges. But, while there are many vexing problems facing Afghanistan’s government and people, a group of academics in Omaha, Nebraska has kept a strong faith in the nation’s future through programs to improve education. VOA’s Greg Flakus has more from Omaha, Nebraska.

Video House Republicans in Chaos as Speaker Favorite Withdraws

The Republican widely expected to become the next speaker of the House of Representatives shocked his colleagues Thursday by announcing he was withdrawing his candidacy. The decision by Majority Leader Kevin McCarthy means the race to succeed retiring Speaker John Boehner is now wide open. VOA National Correspondent Jim Malone reports.

Video German, US Officials Investigate Volkswagen

German officials have taken steps to restore some of the reputation their car industry has lost after a recent Volkswagen diesel emissions scandal. Authorities have searched Volkswagen headquarters and other locations in an effort to identify the culprits in the creation of software that helps cheat on emission tests. Meanwhile, a group of lawmakers in Washington held a hearing to get to the bottom of the cheating strategy that was first discovered in the United States. Zlatica Hoke reports.

Video Why Are Gun Laws So Hard for Congress to Tackle?

Since taking office, President Barack Obama has spoken out or issued statements about 15 mass shootings. The most recent shooting, in which 10 people were killed at a community college, sparked outrage over the nation's gun laws. But changing those laws isn't as easy as many think. VOA's Carolyn Presutti reports.

Video In 'He Named Me Malala,' Guggenheim Finds Normal in Extraordinary

Davis Guggenheim’s documentary "He Named Me Malala" offers a probing look into the life of 18-year-old Malala Yousafsai, the Pakistani teenager who, in 2012, was shot in the head by the Taliban for standing up for her right to education in her hometown in Pakistan's Swat Valley. Guggenheim shows how, since then, Malala has become a symbol not as a victim of brutal violence, but as an advocate for girls’ education throughout the world. VOA’s Penelope Poulou has more.

Video Paintable Solar Cells May Someday Replace Silicon-Based Panels

Solar panels today are still factory-manufactured, with the use of some highly toxic substances such as cadmium chloride. But a researcher at St. Mary’s College, Maryland, says we are close to being able to create solar panels by painting them on a suitable surface, using nontoxic solutions. VOA’s George Putic reports.

VOA Blogs